ISRG is a classic example of the "Razor and Blades" business model. While selling a da Vinci surgical robot (the razor) generates around $1.5M to $2.0M, the real recurring goldmine comes from the "blades", the proprietary instruments, accessories used per surgery, and annual system maintenance fees. Currently, over 70% of its revenue is derived from this recurring revenue, making its financial performance highly resilient against economic cycles.

• High Regulatory Barriers: FDA approvals and global healthcare regulations for medical devices are incredibly lengthy, strict, and costly.
• Intense Surgeon Stickiness: Tens of thousands of top surgeons worldwide have spent years training exclusively on the da Vinci system. For a hospital or surgeon habituated to da Vinci to switch to a competitor, the switching cost and clinical risk are unimaginably high.

ISRG validates a profound business truth: The best businesses do not just make a one-time sale of an expensive product; they use that product to legally and operationally lock in the customer's spending bill for the next decade.